Clinical Academic Training


Immune cell functions in lymphoid malignancies

  • Dr Harriet Walter

About 5000 people in the UK annually develop aggressive lymphoid malignancies.  The genetic and cellular causes underlying their pathogenesis remain unknown.  Since individuals with primary and iatrogenic immunodeficiencies have increased risk of developing lymphoma, we hypothesise that covert defects in the immune system may predispose.

Furthermore, immune cell frequency may be important prognostically and predict treatment responses, particularly with checkpoint inhibitors and bispecific antibody constructs.

The ACF will join a team using multi-omics technologies to characterise immune populations and functions in patients with aggressive lymphoid malignancies.  Single cell approaches will be used to identify not only tumour heterogeneity (using bio-banked biopsy samples) but also rare cell populations.

The ACF will develop B cell antibody panels for CyTOF and undertake analysis of circulating immune cells.  The ACF will perform detailed analysis of peripheral blood and tumour immune B cell populations using this technique to study cellular subsets and identify alterations that may be important in the development of disease.  Results will be correlated with clinical outcome.  They will work alongside members of the team currently utilising 10x single cell RNA sequencing technology (in collaboration with the NUCLEUS genomics facility).

Medical Education

If you are interested in progressing an educational research project within the speciality please visit the medical education project page


Back to top